Comparison of once-daily insulin detemir with insulin glargine added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

Objective To assess the efficacy and safety of insulin detemir or insulin glargine added to oral drug therapy for type 2 diabetes.Methods 90 patients with type 2 diabetes inadequately controlled were randomized to addition of once-daily insulin detemir(Det group) or insulin glargine(Gla group)for 16 weeks,and insulin doses were titrated toward prebreakfast glucose targets of ≤6.0 mmol/L.Outcomes assessed included fasting blood glucose(FBG),HbA1c,risk of hypoglycemia,and body weight.Results At the 16th week,both FPG and HbA1c decreased in two groups,but there was no significant difference between the two groups.6.6% patients in both detemir and glargine experienced hypoglycemia.Mean weight gain of Det group was lower than that of Gla group(P0.05).Conclusion Addition of insulin detemir or insulin glargine to oral drug therapy for type 2 diabetes achieves clinically improvements in glycemic control with low risk of hypoglycemia.Treatment with detemir can achieve extra benefit in reducing weight gain.